Regular Aspirin Use Lowers the Risk of Developing Ovarian Cancer (2/19/2010)
Researchers from the University of Minnesota have reported that women who take aspirin on a regular basis have a decreased risk of developing ovarian cancer compared with non-users. The details of this study were published in the February 8, 2010 issue of Cancer Epidemiology Biomarkers and Prevention.

Symptoms May Do Little to Improve Early Detection of Ovarian Cancer (2/8/2010)
Researchers from the Fred Hutchinson Cancer Research Center have reported that the use of symptoms to trigger medical evaluation for ovarian cancer may not greatly increase early detection of ovarian cancer, and would result in a diagnosis of ovarian cancer in only 1 out of 100 women with symptoms. These results were published in an early online publication in the Journal of the National Cancer Institute on January 28, 2010.

Search for Early Markers of Ovarian Cancer Continues (1/28/2010)
Researchers from the Fred Hutchinson Cancer Research Center have reported that levels of three potential biological markers of ovarian cancer—CA125, human epididymis protein 4, and mesothelin—begin to rise three years before the clinical diagnosis of ovarian cancer; they only become substantially elevated, however, less than a year before diagnosis. Detection of cancer at this stage may not be early enough to improve outcomes. These results were published in the January 6, 2010 issue of the Journal of the National Cancer Institute.

Treatment at High-volume Hospitals Improves Survival in Women with Ovarian Cancer (10/19/2009)
Researchers from Finland have reported that low hospital volume is associated with residual tumor in women with ovarian cancer. The details of this study appeared in the November, 2009 issue of Gynecologic Oncology.

Doxil® and Paraplatin® Superior to Taxol® and Paraplatin for Relapsed Ovarian Cancer (10/1/2009)
Researchers affiliated with the Gynecologic Cancer Intergroup (CCIG) trial CALYPSO have reported that Doxil®, also marketed as Caelyx® and Myocet® (pegylated liposomal doxorubicin) and Paraplatin® (carboplatin) was more effective and better tolerated than Taxol® (paclitaxel) and Paraplatin for partially platinum-sensitive ovarian cancer (patients who relapse between six and 12 months). The details of this study were presented at the Joint ECCO 15 – 34^th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.